Roche Senseonics Agreement

As part of the agreement, Senseonics has granted Roche the rights to promote, market and sell the Eversense product line to diabetes clinics and patients in Germany, Italy and the Netherlands. Headquartered in Basel, Switzerland, the Roche Group is active in more than 100 countries and employed more than 91,700 people worldwide in 2015. In 2015, Roche invested CHF 9.3 billion in research and development and generated sales of CHF 48.1 billion. Genentech in the United States is a 100% member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical in Japan. For more information, see www.roche.com Senseonics has extended and extended its distribution agreement with Roche Diabetes Care for the next two years, giving Big Biotech exclusive rights to sell its implantable glucose monitoring system in 17 other countries, including Brazil, Russia, India and China. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring devices to help people with diabetes live their lives with ease. From the beginning, Senseonics encouraged the integration of new fluorescence sensor technology with smart wearable devices. The Eversense® CGM system has been approved by the FDA for up to 90 days and is available in the United States. The Eversense® XL CGM system has received CE marking for up to 180 days and is available in Europe.

For more information about Senseonics, see www.senseonics.com. Senseonics Holdings, Inc.R. Don Elsey, 301-556-1602Chief Financial Officerdon.elsey@senseonics.com Roche will continue to be Senseonics` exclusive distributor in Europe, the Middle East and Africa, outside Scandinavia and Israel, and will add additional markets in the Asia-Pacific and Latin America regions. The new agreement runs until January 2021. “We are pleased to have Roche as a partner and our distribution agreement is an important step in enabling expanded access to our product,” said Tim Goodnow, CEO and President of Senseonics. “Roche Diabetes Care is a trusted and highly respected leader, with a broad customer base and in-depth knowledge of the needs of people with diabetes and is ideal for the commercialization and commercialization of the Eversense CGM system. Based on fluorescence sensor technology, the sensor is designed to be placed subcutaneously and communicate with the smart transmitter to transmit glucose level wirelessly to a mobile device. . . .